文献速递重症综合管理与镇静镇痛心脑血管急症复苏、休克与脓毒症

脓毒症心肌病生物标志物的研究进展

[Research progress on the biomarkers of sepsis-induced cardiomyopathy].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论脓毒症合并心肌病(SIC)病死率升高超过50%,多种生物标志物对SIC诊断和预后有预测价值,多标志物联合优于单一标志物。

脓毒症是全球主要死因之一,合并脓毒症心肌病(SIC)的患者病死率升高超过50%。早期识别脓毒症尤其是SIC并实施临床干预是降低病死率的关键。近年来SIC诊断和预后生物标志物快速涌现:经典心肌损伤标志物中,心肌肌钙蛋白(cTn)、脑钠肽(BNP)和可溶性生长刺激基因2蛋白(sST2)对SIC预后有预测价值,心型脂肪酸结合蛋白(h-FABP)在诊断方面价值较高;血浆代谢物、微小RNA(miRNA)及新近识别的脓毒症或心血管疾病相关标志物在SIC诊断和预后方面也显示出突出预测价值。多数研究使用单中心临床数据,存在一定局限,仍需更多高质量证据支持。

要点

  • 脓毒症合并SIC患者病死率升高超过50%,早期识别并实施临床干预是降低病死率的重要措施。
  • 经典心肌损伤标志物中,cTn、BNP和sST2对SIC预后有预测价值,h-FABP在诊断方面价值较高。
  • 外泌体miR-150-5p、血miR-155、血miR-378a-3p、血miR-21-3p、血miR-233、血miR-23b、血miR-135、脂质运载蛋白(LCN)、血红素加氧酶-1(HO-1)、成纤维细胞生长因子-21(FGF-21)和生长分化因子-15(GDF-15)对诊断SIC显示出不同程度的预测价值。
  • S100A8/A9蛋白、甘油三酯-葡萄糖(TyG)指数、血管紧张素原II(Ang II)和乳铁蛋白与SIC预后相关。
  • 多个生物标志物联合优于单一标志物,某些组合诊断性能更优;但多数研究为单中心临床数据,仍需更多高质量证据支持。

适用人群与场景

  • 脓毒症患者,尤其是合并脓毒症心肌病(SIC)者。

研究设计与关键结果

  • 综述汇总报告了对SIC有预测价值的生物标志物及多标志物联合诊断和预测的研究。
  • 经典心肌损伤标志物中,心肌肌钙蛋白(cTn)、脑钠肽(BNP)和可溶性生长刺激基因2蛋白(sST2)对SIC预后有预测价值,心型脂肪酸结合蛋白(h-FABP)在诊断方面价值较高。
  • 外泌体miR-150-5p、血miR-155、血miR-378a-3p、血miR-21-3p、血miR-233、血miR-23b、血miR-135、脂质运载蛋白(LCN)、血红素加氧酶-1(HO-1)、成纤维细胞生长因子-21(FGF-21)和生长分化因子-15(GDF-15)对诊断SIC显示出不同程度的预测价值。
  • S100A8/A9蛋白、甘油三酯-葡萄糖(TyG)指数、血管紧张素原II(Ang II)和乳铁蛋白与SIC预后相关。
  • 多标志物联合优于单一标志物,某些组合诊断性能更优。

证据类型、等级与局限

  • 证据类型:综述。
  • 多数研究使用单中心临床数据,存在一定局限,仍需更多高质量证据支持。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis constitutes one of the principal causes of death globally, and the mortality rate of patients complicated with sepsis-induced cardiomyopathy (SIC) surges by over 50%. Early identification of patients with sepsis, particularly SIC, and implementing clinical intervention are vital measures to reduce the mortality. In recent years, biomarkers for the diagnosis and prognosis of SIC have emerged rapidly. Among classical myocardial injury biomarkers, cardiac troponin (cTn), brain natriuretic peptide (BNP), and soluble growth stimulation gene 2 protein (sST2) have predictive value for the prognosis of SIC. Meanwhile, heart-type fatty acid-binding protein (h-FABP) possess relatively high value in diagnosis. Moreover, plasma metabolites, microRNA (miRNA), as well as recently identified markers related to sepsis or cardiovascular diseases also demonstrate outstanding predictive value in both the diagnosis and prognosis of SIC. For instance, exosomal miR-150-5p, blood miR-155, blood miR-378a-3p, blood miR-21-3p, blood miR-233, blood miR-23b, blood miR-135, lipocalin (LCN), heme oxygenase-1 (HO-1), fibroblast growth factor-21 (FGF-21), and growth differentiation factor-15 (GDF-15) show varying degrees of predictive value when it comes to diagnosing SIC. S100A8/A9 protein, triglyceride-glucose (TyG) index, angiotensinogen II (Ang II) and lactoferrin are correlated with the prognosis of SIC. Meanwhile, it has been discovered that the combination of multiple biomarkers outperforms a single biomarker, and certain combinations exhibit superior diagnostic performance. However, most of these studies use single-center clinical data, which has certain limitations and still calls for more high-quality evidence support. Therefore, identifying biomarker combinations that are supported by high-quality evidence, have bedside application potential, and possess high sensitivity and specificity is of crucial importance for the prevention, diagnosis, and treatment of SIC. This review is carried out on the current articles that report biomarkers with predictive value and the diagnosis and prediction of multiple biomarkers in combination, in the hope of continuously optimizing the diagnostic strategy for the specific identification of early SIC.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li H, Hu B. [Research progress on the biomarkers of sepsis-induced cardiomyopathy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40820538. doi:10.3760/cma.j.cn121430-20241112-00924

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。